| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The molecular target is the androgen receptor (AR), where the active metabolite 2-hydroxyflutamide binds competitively and inhibits AR-mediated transcription; flutamide and its metabolites also inhibit AR nuclear translocation and DNA binding, and at higher concentrations they may interact with GABA_A receptors, but AR antagonism is the principal mechanism relevant to prostate cancer therapy.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, flutamide-d7 is metabolized to 2-hydroxyflutamide-d7, which competes with [3H]R1881 for AR binding, inhibits AR-responsive luciferase reporter activity in prostate cancer cells, and suppresses androgen-dependent cell proliferation; the deuterated form retains AR antagonist activity while enabling LC-MS/MS quantification of flutamide and its active metabolite. |
| ln Vivo |
In vivo, oral flutamide-d7 is rapidly converted to 2-hydroxyflutamide, which reduces prostate tumor growth in AR-dependent xenograft models, lowers serum prostate-specific antigen, and produces antiandrogenic effects in androgen-sensitive tissues; the labeled form is used to quantify plasma and tumor concentrations of flutamide and 2-hydroxyflutamide and to relate AR occupancy to antitumor efficacy.
|
| Enzyme Assay |
Noncellular AR binding assays incubate recombinant AR ligand-binding domain or LNCaP cell lysates with [3H]R1881 and increasing concentrations of flutamide-d7 or its 2-hydroxy metabolite; bound and free radioligand are separated by hydroxyapatite or filtration, and IC50 values are derived, with AR-mediated reporter gene activity assessed in parallel.
|
| Cell Assay |
Cellular assays use LNCaP or VCaP prostate cancer cells treated with flutamide-d7; AR nuclear translocation is assessed by immunofluorescence, AR-responsive reporter gene activity by luciferase assay, and cell proliferation by MTT or BrdU incorporation, with AR expression confirmed by immunoblotting.
|
| Animal Protocol |
Animal protocols administer flutamide-d7 orally to mice bearing LNCaP or VCaP xenografts at doses of 10–100 mg/kg; tumor volume, serum PSA, and AR target gene expression in tumor tissue are measured, and plasma and tumor concentrations of flutamide and 2-hydroxyflutamide are quantified by LC-MS/MS to relate AR occupancy to antitumor efficacy.
|
| References |
|
| Molecular Formula |
C11H11F3N2O3
|
|---|---|
| Molecular Weight |
276.211853265762
|
| Exact Mass |
283.116
|
| CAS # |
223134-72-3
|
| Related CAS # |
Flutamide;13311-84-7
|
| PubChem CID |
10802904
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.3
|
| tPSA |
74.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
352
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)C([2H])([2H])[2H]
|
| InChi Key |
MKXKFYHWDHIYRV-NWOXSKRJSA-N
|
| InChi Code |
InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)/i1D3,2D3,6D
|
| Chemical Name |
2,3,3,3-tetradeuterio-N-[4-nitro-3-(trifluoromethyl)phenyl]-2-(trideuteriomethyl)propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6204 mL | 18.1022 mL | 36.2043 mL | |
| 5 mM | 0.7241 mL | 3.6204 mL | 7.2409 mL | |
| 10 mM | 0.3620 mL | 1.8102 mL | 3.6204 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
